郑灿灿,女,1992年8月出生,生物学博士,广州医科大学南山学者骨干人才,特聘教授,博士后合作导师。目前在广州医科大学附属第五医院前沿医学交叉研究中心,研究方向为肿瘤发生发展的作用机制研究及靶向干预。主持国家自然科学基金青年项目1项(2022),中国博士后基金面上项目1项,以及广州医科大学高水平大学人才引进项目。近5年以第一作者或共同第一作者发表SCI论文10余篇,包括:Acta Pharmaceutica Sinica B, 2023; Advanced Science, 2022; Acta Pharm Sin B, 2022; Cell Discovery, 2023; Signal Transduction and Targeted Therapy 2021; Front Pharmacol, 2021 等。
部分代表作如下:
1)Cancan Zheng; Xiaomei Yu; Yiyao Liang; Yidong Zhu; Yan He; Long Liao; Dingkang Wang; Yanming Yang; Xingfeng Yin; Ang Li; Qingyu He; Bin Li ; Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner, Acta Pharmaceutica Sinica B, 2022, 12(3): 1271-1287 ( IF=14.5,A1一区 )
2)Can‐Can Zheng#; Long Liao#; Ya‐Ping Liu#; Yan‐Ming Yang; Yan He; Guo‐Geng Zhang; Shu‐Jun Li; Ting Liu; Wen Wen Xu; Bin Li ; Blockade of Nuclear β ‐Catenin Signaling via Direct Targeting of RanBP3 with NU2058 Induces Cell Senescence to Suppress Colorectal Tumorigenesis, Advanced Science, 2022, 9(34): 2202528 ( IF=17.5,A1一区 )
3)Cancan Zheng#; Xiaomei Yu#; Taoyang Xu#; Zhichao Liu; Zhili Jiang; Jiaojiao Xu; Jing Yang; Guogeng Zhang; Yan He; Han Yang; Xingyuan Shi; Zhigang Li; Jinbao Liu; Wen Wen Xu ; KCTD4 interacts with CLIC1 to disrupt calcium homeostasis and promote metastasis in esophageal cancer, Acta Pharmaceutica Sinica B, 2023, 13(10): 4217-4233 ( IF=14.5,A1一区 )
4)Yan He#; Can-Can Zheng#; Jing Yang#; Shu-Jun Li#; Tao-Yang Xu; Xian Wei; Wen-You Chen; Zhi-Li Jiang; Jiao-Jiao Xu; Guo-Geng Zhang; Chao Cheng; Kui-Sheng Chen; Xing-Yuan Shi; Da-Jiang Qin; Jin-Bao Liu; Bin Li ; Lysine butyrylation of HSP90 regulated by KAT8 and HDAC11 confers chemoresistance, Cell Discovery, 2023, 9(1): 74 (IF=38.1,A1一区 )
5)Xu Wenwen#; Zheng Cancan#; Zuo Qian#; Li Junqi; Hong Pan; Qin Yanru; Guan Xinyuan; He Qingyu; Liao Huaxin; Li Bin ; Genome-wide identification of key regulatory IncRNAs in esophageal cancer metastasis, Signal Transduction and Targeted Therapy, 2021, 6(3): 621-623 (IF=39.3,A1一区 )。
主持基金
1)国家自然科学基金-青年项目,2023.01.01-2025.12.31,在研,主持。
2)广州医科大学高水平大学人才引进项目,2024/03-2024/03,在研,主持。
3)中国博士后面上基金项目,2022.03-2024.03,结题,主持